XDNA — Kelly CRISPR & Gene Editing Technology ETF
Data updated: 2024-11-13
XDNA — Kelly CRISPR & Gene Editing Technology ETF. Holdings, fees, performance and SEC filings.
XDNA Fund Overview
XDNA — Kelly CRISPR & Gene Editing Technology ETF is a US ETF managed by Strategic Trust, categorised as United States Small Cap Blend / Core Information Technology Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Strategic Trust
- Category: United States Small Cap Blend / Core Information Technology Equity
- Assets under management: $2.59M
- 1-year return: -35.8%
- Ticker: XDNA
- SEC CIK: 0001873280
- SEC series ID: S000073961
- Share class ID: C000231237
XDNA Investment Objective and Strategy
Kelly CRISPR & Gene Editing Technology ETF describes its objective and strategy as follows, from its latest prospectus filed with the SEC by Strategic Trust.
Investment objective
The Kelly CRISPR & Gene Editing Technology ETF (the Fund) seeks to track the total return performance, before fees and expenses, of the Strategic CRISPR & Gene Editing Technology Index (the Index).
Principal investment strategy
The Fund employs a passive management (or indexing) investment approach designed to track the total return performance, before fees and expenses, of the Index. The Index is based on a proprietary methodology developed and maintained by Strategic Indexes, LLC (the Index Provider), an affiliate of Kelly Strategic Management, LLC, the Funds investment adviser (the Adviser). Unlike many investment companies, the Fund does not try to beat the Index and does not seek temporary defensive positions when markets decline or appear overvalued other than those indicated in the Index. The Fund will generally use a replication strategy to achieve its investment objective, meaning the Fund will generally invest in all of the component securities of the Index in the same approximate proportions as in the Index.
However, the Fund may use a representative sampling strategy, meaning it may invest in a sample of the securities in the Index whose risk, return, and other characteristics closely resemble the risk, return, and other characteristics of the Index as a whole, when the Funds Sub-Adviser believes it is in the best interests of the Fund ( e.g. , when replicating the Index involves practical difficulties or substantial costs, an Index constituent becomes temporarily illiquid, unavailable, or less liquid, or as a result of legal restrictions or limitations that apply to the Fund but not to the Index). The Fund is considered to be non-diversified, which means that it may invest more of its assets in the securities of a single issuer or a smaller number of issuers than if it were a diversified fund.
The Index The Index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the following (DNA Modification Technology Business): CRISPR & Gene Editing Technology DNA modification technologies for a variety of applications including basic biological research, development of biotechnological products, and for the treatment of diseases. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and gene editing technology refers to those methods that allow a scientist to change the DNA of an organism. CRISPR & gene editing technology enables genetic elements to be mutated, silenced, induced ore replaced.
The most common use of DNA modification technology is the targeting of cells within the body to treat genetic disease. Gene Editing Development Solutions Deep scientific, technical and clinical development experience, potentially along with an intellectual property portfolio. Such companies shall have rights to develop CRISPR or gene-editing based therapeutic products or targets and/or jointly develop potential products with CRISPR & gene editing technology companies to create a new class of therapeutic products. Gene Editing Sequencing Solutions Next-generation sequencing that may be used at various stages of a genome editing workflow. These companies provide sequencing methods to determine the impact of an edited sequence on the structured function of genes and analysis tools for CRISPR and gene splicing and editing.
Construction of the Index begins with equity securities listed on an exchange in a developed country. Companies are then considered for inclusion in the Index based on an analysis of the companys source of revenues and profits. A company is eligible for inclusion in the Index if, according to a public filing, it generates a majority of its revenue or profits from one of the activities described above (DNA Modification Technology Companies). The Index Provider screens for the source of a companys revenues and profits using information in regulatory filings ( e.g. , financial statements, annual reports, investor presentations), analyst reports, and industry-specific trade publications. Equity securities included in the Index include common stocks, real estate investment trusts (REITs), depositary receipts, and preferred stocks.
As of October 31, 2022, companies listed in the following countries were eligible for inclusion in the Index: Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Singapore, Spain, Sweden, Switzerland, the United Kingdom, and the United States. Eligible Companies identified by the Index Provider are added to the Index, subject to meeting the investibility requirements described below. The Index may include small-, mid-, and large-capitalization companies. The Index is subject to a maximum of 60 constituents, with a maximum of 42 constituents from the Gene Editing and Technology sub-sector and 9 constituents from each of the Gene Editing and Development Solutions and Gene Editing Sequencing Solutions sub-sectors.
Where the number of eligible constituents exceeds the maximum allowable, the Fund will rank the constituents by float adjusted market capitalization and take the largest constituents until it has reached the maximum number allowed. At the time of each quarterly rebalance and reconstitution of the Index, Index constituents must meet investibility requirements, including: a market capitalization of at least $300 million; a 3-month average daily traded value greater than or equal to $1 million; a free float ( i.e. , the proportion of shares that are publicly available) of at least 20%; and a trading price of not greater than $50,000. The Index is reconstituted and rebalanced ( i.e. , companies are added or deleted and weights are reset based on Index rules) quarterly, after the close of business on the third Friday of each of March, June, September, and December (the Rebalance Date).
For each rebalance and reconstitution of the Index, Index constituents are determined based on data as of the last business day in each of February, May, August, and November (the Selection Date). As of each rebalance date, each constituent is market capitalization-weighted, subject to a maximum of 10.00% weight and a minimum of 0.25% weight for each constituent. Any weight removed from an indexs constituents due to a limit is combined, and the combined weight then distributed proportionately (according to their index weighting) across the uncapped constituents of the index. The Fund rebalances its portfolio in accordance with its Index, and, therefore, any changes to the Indexs rebalance schedule will result in corresponding changes to the Funds rebalance schedule. As of September 30, 2022, the Index had 23 constituents, 2 of which were listed on a non-U.S.
exchange. The Index was established in 2021 and is owned by the Index Provider. The Funds Investment Strategy Under normal circumstances, the Fund invests at least 80% of its net assets (plus borrowings for investment purposes) in DNA Modification Technology Companies.The foregoing policy may be changed without shareholder approval upon 60 days written notice to shareholders. To the extent the Index concentrates (i.e., holds more than 25% of its total assets) in any industry or group of related industries, the Fund will concentrate its investments to approximately the same extent as the Index. As of September 30, 2022, the Index was concentrated in companies in the genomics and biotechnology industries.
XDNA Holdings
Top 10 holdings of Kelly CRISPR & Gene Editing Technology ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| CRISPR Therapeutics AG | 14.70% |
| Beam Therapeutics Inc | 13.36% |
| Thermo Fisher Scientific Inc | 9.93% |
| Intellia Therapeutics Inc | 8.73% |
| Prime Medicine Inc | 6.05% |
| Editas Medicine Inc | 5.87% |
| Caribou Biosciences Inc | 4.94% |
| Verve Therapeutics Inc | 4.35% |
| Poseida Therapeutics Inc | 4.28% |
| AbbVie Inc | 4.01% |
XDNA Portfolio Allocation
Asset-class allocation of Kelly CRISPR & Gene Editing Technology ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.6% |
| Cash & Equivalents | 0.4% |
XDNA Performance
Total returns for XDNA (as of 2026-10-01), from SEC filings.
| Period | Total return |
|---|---|
| 1 year | -35.8% |
XDNA Risk Information
Risk metrics for XDNA, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 37.9%
XDNA Costs and Fees
XDNA costs about $78 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.78%
- Gross expense ratio: 0.78%
- Portfolio turnover: 23%
- Brokerage commissions: 17.23 bps of average net assets (SEC N-CEN)
XDNA Cashflows
Over the 12 months to 2023-11, Kelly CRISPR & Gene Editing Technology ETF had net inflows of $1.77M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2023-11 | $337.06K |
| 2023-10 | $0 |
| 2023-09 | $0 |
| 2023-08 | $206.19K |
| 2023-07 | $0 |
| 2023-06 | $0 |
XDNA Debt Constituents
No individual debt constituents are reported in Kelly CRISPR & Gene Editing Technology ETF's latest SEC N-PORT filing.
XDNA Prospectus and SEC Filings
Official Kelly CRISPR & Gene Editing Technology ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2022-12-22
- Prospectus supplement (497) — filed 2021-12-23
- Portfolio holdings (N-PORT) — filed 2024-01-24
- Portfolio holdings (N-PORT) — filed 2023-10-27
- Portfolio holdings (N-PORT) — filed 2023-07-20
- Annual census (N-CEN) — filed 2024-11-13
- Annual census (N-CEN) — filed 2023-11-14
- Annual census (N-CEN) — filed 2022-11-14
Related Funds
Other United States Small Cap Blend / Core Information Technology Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.